Assessment of peripheral blood CD4+ adenosine triphosphate activity in patients with rheumatoid arthritis

Modern Rheumatology

Volumn 23, Issue 1, 2013, Pages 19-27

  Akimoto, Masaki ^a   Yunoue, Shingo ^b   Otsubo, Hideo ^c   Yoshitama, Tamami ^c   Kodama, Kunihiro ^c   Matsushita, Kakushi ^a   Suruga, Yukio ^a   Kozako, Tomohiro ^b   Toji, Shingo ^d   Hashimoto, Sachi ^d   Uozumi, Kimiharu ^a,b   Matsuda, Takemasa ^c   Arima, Naomichi ^a,b  

^a KAGOSHIMA UNIVERSITY HOSPITAL   (Japan)

^b KAGOSHIMA UNIVERSITY   (Japan)

^c Kagoshima Red Cross Hospital   (Japan)

^d Medical & Biological Laboratories Co Ltd   (Japan)

Author keywords

CD4+ cell; ImmuKnow; Immune cell function; Infection; Rheumatoid arthritis

Indexed keywords

ADENOSINE TRIPHOSPHATE; PHYTOHEMAGGLUTININ;

ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ACTIVITY; FEMALE; HUMAN; IMMUNOASSAY; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS;

ADENOSINE TRIPHOSPHATE; ADULT; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CD4-POSITIVE T-LYMPHOCYTES; FEMALE; HUMANS; IMMUNOASSAY; IMMUNOSUPPRESSIVE AGENTS; INFECTION; JOINTS; MALE; MIDDLE AGED; PHYTOHEMAGGLUTININS; PREDICTIVE VALUE OF TESTS; RISK; SEVERITY OF ILLNESS INDEX;

EID: 84872500945     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.1007/s10165-012-0621-1     Document Type: Article

References (28)

1. Kowalski RJ, Post DR, Mannon RB, Sebastian A, Wright HI, Sigle G, et al. Assessing relative risks of infection and rejection: a meta-analysis using an immune function assay. Transplantation. 2006;82:663-8.
2. Sanchez-Velasco P, Rodrigo E, Valero R, Ruiz JC, Fernandez-Fresnedo G, Lopez-Hoyos M, et al. Intracellular ATP concentrations of CD4 cells in kidney transplant patients with and without infection. Clin Transplant. 2008;22:55-60.
3. Gupta S, Mitchell JD, Markham DW, Mammen PP, Patel PC, Kaiser PA, et al. Utility of the Cylex assay in cardiac transplant recipients. J Heart Lung Transplant. 2008;27:817-22.
4. Bhorade SM, Janata K, Vigneswaran WT, Alex CG, Garrity ER. Cylex ImmuKnow assay levels are lower in lung transplant recipients with infection. J Heart Lung Transplant. 2008;27:990-4.
5. Kowalski R, Post D, Schneider MC, Britz J, Thomas J, Deierhoi M, et al. Immune cell function testing: an adjunct to therapeutic drug monitoring in transplant patient management. Clin Transplant. 2003;17:77-88.
6. Serban G, Whittaker V, Fan J, Liu Z, Manga K, Khan M, et al. Significance of immune cell function monitoring in renal transplantation after thymoglobulin induction therapy. Hum Immunol. 2009;70:882-90.
7. Pareja JG, Garland R, Koziel H. Use of adjunctive corticosteroids in severe adult non-HIV Pneumocystis carinii pneumonia. Chest. 1998;113:1215-24.
8. Kovacs JA, Hiemenz JW, Macher AM, Stover D, Murray HW, Shelhamer J. Pneumocystis carinii pneumonia: a comparison between patients with the acquired immunodeficiency syndrome and patients with other immunodeficiencies. Ann Intern Med. 1984;100:663-71.
9. Smolen JS, Landewe R, Breedveld FC, Dougados M, Emery P, Gaujoux-Viala C, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis. 2010;69:964-75.
10. Balandraud N, Roudier J, Roudier C. What are the links between Epstein-Barr virus, lymphoma, and tumor necrosis factor antagonism in rheumatoid arthritis? Semin Arthritis Rheum. 2005;34:31-3.
11. Dias C, Isenberg DA. Susceptibility of patients with rheumatic diseases to B-cell non-Hodgkin lymphoma. Nat Rev Rheumatol. 2011;7:360-8.
12. Harrington LE, Hatton RD, Mangan PR, Turner H, Murphy TL, Murphy KM, et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol. 2005;6:1123-32.
13. Park H, Li Z, Yang XO, Chang SH, Nurieva R, Wang Y, et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol. 2005;6:1133-41.
14. Spriggs MK. Interleukin-17 and its receptor. J Clin Immunol. 1997;17:366-9.
15. Acosta-Rodriguez EV, Napoletani G, Lanzavecchia A, Sallusto F. Interleukins 1β and 6 but not transforming growth factor-β are essential for the differentiation of interleukin 17-producing human T helper cells. Nat Immunol. 2007;8:942-9.
16. Chen Z, Tato CM, Muul L, Laurence A, O'Shea JJ. Distinct regulation of interleukin-17 in human T helper lymphocytes. Arthritis Rheum. 2007;56:2936-46.
17. Wilson NJ, Boniface K, Chan JR, McKenzie B, Blumenschein WM, Mattson JD, et al. Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol. 2007;8:950-7.
18. van Beelen AJ, Zelinkova Z, Taanman-Kueter EW, Muller FJ, Hommes DW, Zaat SAJ, et al. Stimulation of the intracellular bacterial sensor NOD2 programs dendritic cells to promote interleukin-17 production in human memory T cells. Immunity. 2007;27:1-10.
19. Ouyang W, Kolls JK, Zheng Y. The biological functions of T helper 17 cell effector cytokines in inflammation. Immunity. 2008;28:454-67.
20. Bernatsky S, Hudson M, Suissa S. Anti-rheumatic drug use and risk of serious infections in rheumatoid arthritis. Rheumatology. 2007;46:1157-60.
21. Lacaille D, Guh DP, Abrahamowicz M, Anis AH, Esdaile JM. Use of nonbiologic disease-modifying antirheumatic drugs and risk of infection in patients with rheumatoid arthritis. Arthritis Rheum. 2008;59:1074-81.
22. Franklin J, Lunt M, Bunn D, Symmons D, Silman A. Risk and predictors of infection leading to hospitalisation in a large primary-care-derived cohort of patients with inflammatory polyarthritis. Ann Rheum Dis. 2007;66:308-12.
23. Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE. Predictors of infection in rheumatoid arthritis. Arthritis Rheum. 2002;46:2294-300.
24. Smitten AL, Choi HK, Hochberg MC, Suissa S, Simon TA, Testa MA, et al. The risk of hospitalized infection in patients with rheumatoid arthritis. J Rheumatol. 2008;35:387-93.
25. Wolfe F, Caplan L, Michaud K. Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy. Arthritis Rheum. 2006;54:628-34.
26. Edwards CJ, Cooper C, Fisher D, Field M, van Staa TP, Arden NK. The importance of the disease process and disease-modifying antirheumatic drug treatment in the development of septic arthritis in patients with rheumatoid arthritis. Arthritis Rheum. 2007;57:1151-7.
27. Dixon WG, Kezouh A, Bernatsky S, Suissa S. The influence of systemic glucocorticoid therapy upon the risk of non-serious infection in older patients with rheumatoid arthritis: a nested case-control study. Ann Rheum Dis. 2011;70:956-60.
28. Cronstein BN, Eberle MA, Gruber HE, Levin RI. Methotrexate inhibits neutrophil function by stimulating adenosine release from connective tissue cells. Proc Natl Acad Sci USA. 1991;88:2441-5.